Enliven Therapeutics ELVN Proceeds From Issuance Of Common Stock Under Sales Agreement Net Of Issuance Costs
Proceeds From Issuance Of Common Stock Under Sales Agreement Net Of Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept elvn:ProceedsFromIssuanceOfCommonStockUnderSalesAgreementNetOfIssuanceCosts.
The official record: Enliven Therapeutics’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's proceeds from issuance of common stock under sales agreement net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's proceeds from issuance of common stock under sales agreement net of issuance costs?
- Enliven Therapeutics (ELVN) reported proceeds from issuance of common stock under sales agreement net of issuance costs of $0 in Q4 2025.
- How has Enliven Therapeutics's proceeds from issuance of common stock under sales agreement net of issuance costs changed year-over-year?
- Enliven Therapeutics's proceeds from issuance of common stock under sales agreement net of issuance costs decreased by 100.0% year-over-year, from $9.8M to $0.
- What does proceeds from issuance of common stock under sales agreement net of issuance costs mean?
- This captures the net cash proceeds from the sale of common stock through an 'at-the-market' or similar sales agreement. This financing method allows the company to raise capital incrementally over time based on prevailing market conditions.